Celltrion Seeks Australian Approval for Vsecuma
Celltrion has applied to Australia's Therapeutic Goods Administration for approval of Vsecuma, a biosimilar of Novartis' Cosentyx.
Updated on Nov. 12, 2026 in Arthritis

Celltrion has applied to Australia's Therapeutic Goods Administration for approval of Vsecuma, its biosimilar of Novartis' secukinumab product Cosentyx. The application covers four indications: plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
Why it matters
The indications sought in Australia match those already approved for Cosentyx in Canada, where Celltrion has also applied. Approval would allow Celltrion to enter the secukinumab market, which is a large segment of biologic treatments.
A clinical trial involving 172 healthy subjects demonstrated pharmacokinetic equivalence to the original drug, based on the sponsor's reported results. The source does not say whether patient-based trials were conducted or when the Australian regulator will rule on the application.
The players
Celltrion
Celltrion is a South Korean biopharmaceutical company that develops and markets biosimilar medicines.
Novartis
Novartis is a Swiss multinational pharmaceutical company and the originator of Cosentyx (secukinumab).
The details
Vsecuma, developed under the name CT-P55, was evaluated in a trial that showed similar safety and immunogenicity profiles to Cosentyx. Celltrion previously submitted Vsecuma applications in Canada, South Korea, the United States and Europe, and plans to use its local distribution networks to support market entry in Australia.
Timeline
May: Celltrion submitted its Vsecuma application in Canada.
June: Celltrion submitted its Vsecuma application in South Korea.
July: Celltrion submitted Vsecuma applications in the United States and Europe.
12 November: Celltrion announced its Australian application for Vsecuma.
Big Picture
Vsecuma's filings across Canada, South Korea, the United States, Europe and now Australia follow a pattern of biosimilar makers pursuing approval in major markets once a reference biologic has established broad sales, as Cosentyx did with roughly 6.668 billion dollars in global sales last year. Australian approval would extend that pattern into a new market where Cosentyx is already used for the same four indications.
If approved, Vsecuma would give patients in Australia an additional option for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Any change to prescribing or cost would depend on the regulator's decision and subsequent listing, which the source does not address.
The takeaway
Biosimilars aim to offer treatment options that match an established biologic in safety and effectiveness, which can broaden access over time. Patients and clinicians should watch for the regulator's decision before expecting any change in available options.
Further reading
Explore more on Arthritis treatments and the drugs used to manage the condition.










